Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
作者： Per Eystein Lønning , Emilio Bajetta , Robin Murray , Michele Tubiana-Hulin , Peter D Eisenberg
DOI: 10.1200/JCO.2000.18.11.2234
关键词:
摘要: PURPOSE: To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who had progressive disease (PD) after treatment nonsteroidal inhibitor. PATIENTS AND METHODS: In this phase II trial, eligible patients were treated exemestane 25 mg daily (n = 241) followed, at time PD was determined, by 100 58). RESULTS: On basis intent-to-treat analysis independent review, produced objective responses 6.6% (95% confidence interval [CI], 3.8% to 10.6%) overall success (complete response + partial no change for 24 weeks or longer) 24.3% CI, 19.0% 30.2%). The median durations 58.4 49.7 71.1 weeks) 37.0 35.0 39.4 weeks), respectively. Increasing dose upon development one par...
elsevier.com
sci-hub.se 参考文章(28)
Gretchen G. Kimmick, Hyman B. Muss, Endocrine therapy in metastatic breast cancer. Cancer treatment and research. ,vol. 94, pp. 231- 254 ,(1998) , 10.1007/978-1-4615-6189-7_13
A Buzdar, W Jonat, A Howell, S E Jones, C Blomqvist, C L Vogel, W Eiermann, J M Wolter, M Azab, A Webster, P V Plourde, Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Journal of Clinical Oncology. ,vol. 14, pp. 2000- 2011 ,(1996) , 10.1200/JCO.1996.14.7.2000
G Ornati, J Paolini, P E Lonning, G Piscitelli, E Di Salle, S Kvinnsland, D C Johannessen, M G Zurlo, T Engan, Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clinical Cancer Research. ,vol. 3, pp. 1101- 1108 ,(1997)
P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, W Bezwoda, G Gardin, A Gudgeon, M Morgan, A Fornasiero, W Hoffmann, J Michel, T Hatschek, T Tjabbes, H A Chaudri, U Hornberger, P F Trunet, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology. ,vol. 16, pp. 453- 461 ,(1998) , 10.1200/JCO.1998.16.2.453
FA MacNeill, AL Jones, S Jacobs, PE Lønning, TJ Powles, M Dowsett, The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer. ,vol. 66, pp. 692- 697 ,(1992) , 10.1038/BJC.1992.339
E. di Salle, G. Ornati, D. Giudici, M. Lassus, T.R.J. Evans, R.C. Coombes, Exemestane (FCE 24304), a new steroidal aromatase inhibitor. The Journal of Steroid Biochemistry and Molecular Biology. ,vol. 43, pp. 137- 143 ,(1992) , 10.1016/0960-0760(92)90198-R
Angela M.H. Brodie, Wesley M. Garrett, James R. Hendrickson, Chon-Hwa Tsai-Morris, Patrick A. Marcotte, Cecil H. Robinson, Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo Steroids. ,vol. 38, pp. 693- 702 ,(1981) , 10.1016/0039-128X(81)90087-8
J. Geisler, D.C. Johannessen, G. Anker, P.E. Lønning, Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects European Journal of Cancer. ,vol. 32, pp. 789- 792 ,(1996) , 10.1016/0959-8049(95)00623-0
Robin Murray, Paula Pitt, Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer Breast Cancer Research and Treatment. ,vol. 35, pp. 249- 253 ,(1995) , 10.1007/BF00665976
P.E. Lønning, Pharmacology of new aromatase inhibitors The Breast. ,vol. 5, pp. 202- 208 ,(1996) , 10.1016/S0960-9776(96)90094-6